Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients

被引:45
作者
Putzki, Norman [1 ]
Katsarava, Zaza [1 ]
Vago, Susanne [1 ]
Diener, H. C. [1 ]
Limmroth, Volker [1 ]
机构
[1] Univ Hosp Essen, Dept Neurol, Essen, Germany
关键词
multiple sclerosis; fatigue; Fatigue Severity Scale;
D O I
10.1159/000111876
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Fatigue is one of the most frequent and most disabling symptoms in multiple sclerosis (MS). We investigated the possible association of the MS-related fatigue syndrome with the available disease-modifying therapies and the main disease characteristics in a cross-sectional study on 320 consecutive patients. The prevalence of severe fatigue (Fatigue Severity Scale score >= 5) was 50%. In a multivariate regression model controlling for age, disease subtype, duration and disability we did not find a significant association between the use of immunosuppressive or immunomodulatory drugs compared to no treatment (OR = 1.34, p = 0.38 for immunosuppressants; OR = 0.95, p = 0.85 for immune-modulating agents). Although all used disease-modifying agents successfully reduce disease activity and inflammation, they do not appear to exhibit a significant effect on MS-related fatigue. Copyright (C) 2007 S. Karger AG, Basel.
引用
收藏
页码:136 / 142
页数:7
相关论文
共 34 条
  • [1] Bakshi R, 2000, MULT SCLER J, V6, P181, DOI 10.1191/135245800701566052
  • [2] Fatigue in multiple sclerosis: Cross-sectional correlation with brain MRI findings in 71 patients
    Bakshi, R
    Miletich, RS
    Henschel, K
    Shaikh, ZA
    Janardhan, V
    Wasay, M
    Stengel, LM
    Ekes, R
    Kinkel, PR
    [J]. NEUROLOGY, 1999, 53 (05) : 1151 - 1153
  • [3] Bergamaschi R, 1997, FUNCT NEUROL, V12, P247
  • [4] BRANAS P, 2000, HEALTH TECHNOL ASSES, V4, P41
  • [5] Interferon-beta(1b) treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis
    Brod, SA
    Marshall, GD
    Henninger, EM
    Sriram, S
    Khan, M
    Wolinsky, JS
    [J]. NEUROLOGY, 1996, 46 (06) : 1633 - 1638
  • [6] COLOSIMO C, 1995, ACTA NEUROL SCAND, V92, P353
  • [7] COLOSIMO C, 1994, NEUROPSY NEUROPSY BE, V7, P194
  • [8] Risk of cancer from azathioprine therapy in multiple sclerosis: A case-control study
    Confavreux, C
    Saddier, P
    Grimaud, J
    Moreau, T
    Adeleine, P
    Aimard, G
    [J]. NEUROLOGY, 1996, 46 (06) : 1607 - 1612
  • [9] Changes in plasma cytokines induced by interferon-β1a treatment in patients with multiple sclerosis
    Duddy, ME
    Armstrong, MA
    Crockard, AD
    Hawkins, SA
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 1999, 101 (01) : 98 - 109
  • [10] THE IMPACT OF FATIGUE ON PATIENTS WITH MULTIPLE-SCLEROSIS
    FISK, JD
    PONTEFRACT, A
    RITVO, PG
    ARCHIBALD, CJ
    MURRAY, TJ
    [J]. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1994, 21 (01) : 9 - 14